EUCTR2019-001512-34-ES进行中（未招募）1 期
A PHASE 2, OPEN-LABEL, SINGLE-ARM TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HER2-POSITIVE, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PROGRESSED ON OR AFTER A TRASTUZUMAB-CONTAINING REGIME
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Key Inclusion Criteria:
- •- Men or women =18 years old (Please follow local regulatory requirements if the legal age of consent for study participation is >18 years old.)
- •- Has pathologically documented gastric or GEJ cancer that is:
- •- Unresectable or metastatic
- •- Centrally confirmed HER2-positive disease (immunohistochemistry [IHC]3+, IHC2+/in-situ hybridization [ISH]+) as determined according to American Society of Clinical Oncology – College of American Pathologists (ASCO-CAP) guidelines based on a new tissue sample obtained after progression on or after a trastuzumabcontaining regimen. If a tissue sample was already collected after discontinuation of first-line treatment with a trastuzumab-containing regimen, it is acceptable to consider this a new biopsy for the purpose of this study.
- •- Experienced disease progression during or after first-line therapy with a trastuzumab-containing regimen (brand or approved biosimilar). Note: Prior adjuvant therapy with a trastuzumab-containing regimen can be counted as a line of therapy if the subject progressed on or within 6 months of completing adjuvant therapy.
- •- Has at least 1 measurable lesion per RECIST v1.1 as confirmed by independent central review.
- •- Has left ventricular ejection fraction (LVEF) =50% within 28 days before enrollment per echocardiogram
- •(ECHO)/multigated acquisition (MUGA) scan.
- •- Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 4.5 months after the last dose of study drug.
- •- Adequate renal function, defined as creatinine clearance =30 mL/min, as calculated using the Cockcroft-Gault equation.
- •- Adequate hepatic function, defined as total bilirubin =1.5 × upper limit of normal (ULN); serum albumin =2.8 g/dL; aspartate transaminase (AST)/alanine transaminase (ALT) =3 × ULN in the absence of liver metastases or =5 × ULN in the presence of liver metastases.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 36
排除标准
- •Key Exclusion Criteria:
- •- Use of anticancer therapy after first-line treatment with a trastuzumab-containing regimen.
- •- Uncontrolled or significant cardiovascular disease, including any of the following:
- •- History of myocardial infarction (MI) within 6 months before enrollment
- •- History of symptomatic congestive heart failure (New York Heart Association Class II to IV)
- •- Troponin levels consistent with MI as defined according to the manufacturer within 28 days prior to enrollment
- •- History of unstable angina or serious cardiac arrhythmia requiring treatment
- •- Corrected QT interval (QTc) prolongation to >470 ms (females) or >450 ms (male) based on Screening triplicate 12-lead electrocardiogram (ECG)
- •- History of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required corticosteroid therapy or has current ILD/pneumonitis or is suspected to have such diseases by imaging during Screening.
- •- Clinically significant corneal disease, in the opinion of the Investigator.
- •- Pleural effusion, ascites, or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART). (Drainage and CART are not allowed within 2 weeks prior to or during Screening.)
- •- Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- •- Subjects with clinically inactive brain metastases may be included in the study.
- •- Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (1 week for stereotactic radiotherapy).
研究者
相似试验
进行中（未招募）
1 期
DS-8201a in HER2-positive Gastric Cancer that cannot be surgically removed or has spreadEUCTR2019-001512-34-BEDaiichi Sankyo Inc.79
进行中（未招募）
1 期
DS-8201a in HER2-positive Gastric Cancer that cannot be surgically removed or has spreadnresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumabcontaining regimenMedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864EUCTR2019-001512-34-ITDAIICHI SANKYO INC.72
进行中（未招募）
1 期
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants =10 Years of Ageprevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup BMedDRA version: 20.0Level: LLTClassification code 10027276Term: Meningococcal meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002588-24-CZPfizer Inc.50
进行中（未招募）
1 期
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants =10 Years of Ageprevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup BMedDRA version: 20.0Level: LLTClassification code 10027276Term: Meningococcal meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002588-24-PLPfizer Inc.50
已完成
2 期
A Phase 2 study of TAS-115 in patients with CRPCPatient with castration resistant prostate cancerJPRN-jRCT2080223393Taiho Pharmaceutical Co., Ltd.50